PUBLISHER: IMARC | PRODUCT CODE: 1820204
PUBLISHER: IMARC | PRODUCT CODE: 1820204
The global malaria diagnostics market size reached USD 876.6 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,415.9 Million by 2033, exhibiting a growth rate (CAGR) of 5.47% during 2025-2033.
Malaria diagnostics refers to the clinical tests conducted to detect the presence of the infection in individuals. Malaria is caused by the bite of an infected female Anopheles mosquito, which leads to the transfer of Plasmodium parasites into the body. Some common symptoms include fever, fatigue, nausea and headaches. The infection is diagnosed through various rapid diagnostics, microscopy and molecular diagnostic tests. These tests use antigen detection and serology techniques using indirect immunofluorescence (IFA) or enzyme-linked immunosorbent assay (ELISA). They are widely used in hospitals, laboratories, clinics, research institutes and diagnostic centers.
The increasing prevalence of malaria across the globe is one of the key factors creating a positive outlook for the market. Malaria is a life-threatening infection that has caused a significant loss of human lives, especially in developing nations. However, rising awareness among the masses regarding the available diagnostic and treatment alternatives for malaria is providing a thrust to the market growth. Healthcare centers and diagnostic laboratories are widely adopting microscopic diagnostics to identify the parasite at different stages and design suitable treatment plans. Additionally, various technological advancements, such as the development of the Quantitative Buffy Coat (QBC) method and peripheral blood smear technique for diagnosing malaria, are acting as other growth-inducing factors. In line with this, the availability of Point-of-Care (POC) diagnostic devices for enhanced accuracy is also contributing to the growth of the market. Other factors, including rising healthcare expenditure capacities of the masses, along with the implementation of favorable government policies promoting public health, are anticipated to drive the market toward growth.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Access Bio, Beckman Coulter Inc. (Danaher Corporation), bioMerieux SA (Compagnie Merieux Alliance), Bio-Rad Laboratories Inc., Nikon Corporation, Novartis AG, Olympus Corporation, Premier Medical Corporation Pvt. Ltd., Siemens Healthcare GmbH (Siemens AG), Sysmex Corporation and Thermo Fisher Scientific Inc.